Something Old and Something New About Molecular Diagnostics in Gliomas

Craig Horbinski

doi:10.1016/j.path.2012.09.001

Something Old and Something New About Molecular Diagnostics in Gliomas

Craig Horbinski^*

^*Corresponding author for this work

Pathology

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

Progress in understanding the molecular biology of neoplasms has been driven by remarkable improvements in molecular biology techniques, creating a rapidly moving field in which even subspecialists struggle to keep abreast. Nowhere is this more clearly demonstrated than in neuro-oncology, wherein molecular diagnostics can wring more clinically useful information out of small biopsies than ever. The biologic and practical aspects of 4 key molecular biomarkers in gliomas are discussed, including 2 that have been known for some time (1p/19q codeletion and epidermal growth factor receptor [EGFR] amplification) as well as 2 whose relevance was discovered via advanced whole-genome assays (IDH1/2 mutations and BRAF alterations).

Original language	English (US)
Pages (from-to)	919-939
Number of pages	21
Journal	Surgical Pathology Clinics
Volume	5
Issue number	4
DOIs	https://doi.org/10.1016/j.path.2012.09.001
State	Published - Dec 1 2012

Keywords

Biomarkers
Central nervous system cancer
Glioma
Molecular pathology
Neuro-oncology

ASJC Scopus subject areas

Surgery
Pathology and Forensic Medicine

Access to Document

10.1016/j.path.2012.09.001

Fingerprint Dive into the research topics of 'Something Old and Something New About Molecular Diagnostics in Gliomas'. Together they form a unique fingerprint.

Cite this

@article{4da9dda21cd8448b92675aa14467d199,

title = "Something Old and Something New About Molecular Diagnostics in Gliomas",

abstract = "Progress in understanding the molecular biology of neoplasms has been driven by remarkable improvements in molecular biology techniques, creating a rapidly moving field in which even subspecialists struggle to keep abreast. Nowhere is this more clearly demonstrated than in neuro-oncology, wherein molecular diagnostics can wring more clinically useful information out of small biopsies than ever. The biologic and practical aspects of 4 key molecular biomarkers in gliomas are discussed, including 2 that have been known for some time (1p/19q codeletion and epidermal growth factor receptor [EGFR] amplification) as well as 2 whose relevance was discovered via advanced whole-genome assays (IDH1/2 mutations and BRAF alterations).",

keywords = "Biomarkers, Central nervous system cancer, Glioma, Molecular pathology, Neuro-oncology",

author = "Craig Horbinski",

year = "2012",

month = dec,

day = "1",

doi = "10.1016/j.path.2012.09.001",

language = "English (US)",

volume = "5",

pages = "919--939",

journal = "Surgical Pathology Clinics",

issn = "1875-9181",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - Something Old and Something New About Molecular Diagnostics in Gliomas

AU - Horbinski, Craig

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Progress in understanding the molecular biology of neoplasms has been driven by remarkable improvements in molecular biology techniques, creating a rapidly moving field in which even subspecialists struggle to keep abreast. Nowhere is this more clearly demonstrated than in neuro-oncology, wherein molecular diagnostics can wring more clinically useful information out of small biopsies than ever. The biologic and practical aspects of 4 key molecular biomarkers in gliomas are discussed, including 2 that have been known for some time (1p/19q codeletion and epidermal growth factor receptor [EGFR] amplification) as well as 2 whose relevance was discovered via advanced whole-genome assays (IDH1/2 mutations and BRAF alterations).

AB - Progress in understanding the molecular biology of neoplasms has been driven by remarkable improvements in molecular biology techniques, creating a rapidly moving field in which even subspecialists struggle to keep abreast. Nowhere is this more clearly demonstrated than in neuro-oncology, wherein molecular diagnostics can wring more clinically useful information out of small biopsies than ever. The biologic and practical aspects of 4 key molecular biomarkers in gliomas are discussed, including 2 that have been known for some time (1p/19q codeletion and epidermal growth factor receptor [EGFR] amplification) as well as 2 whose relevance was discovered via advanced whole-genome assays (IDH1/2 mutations and BRAF alterations).

KW - Biomarkers

KW - Central nervous system cancer

KW - Glioma

KW - Molecular pathology

KW - Neuro-oncology

UR - http://www.scopus.com/inward/record.url?scp=84869748735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869748735&partnerID=8YFLogxK

U2 - 10.1016/j.path.2012.09.001

DO - 10.1016/j.path.2012.09.001

M3 - Review article

C2 - 23459421

AN - SCOPUS:84869748735

VL - 5

SP - 919

EP - 939

JO - Surgical Pathology Clinics

JF - Surgical Pathology Clinics

SN - 1875-9181

IS - 4

ER -